Sökning: WFRF:(Garaci F.) > (2015-2019) > Evolving Evidence f...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05024naa a2200805 4500 | |
001 | oai:gup.ub.gu.se/224867 | |
003 | SwePub | |
008 | 240528s2015 | |||||||||||000 ||eng| | |
024 | 7 | a https://gup.ub.gu.se/publication/2248672 URI |
024 | 7 | a https://doi.org/10.3233/jad-1502022 DOI |
040 | a (SwePub)gu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Lista, S.4 aut |
245 | 1 0 | a Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline |
264 | 1 | b IOS Press,c 2015 |
520 | a There is evolving evidence that individuals categorized with subjective cognitive decline (SCD) are potentially at higher risk for developing objective and progressive cognitive impairment compared to cognitively healthy individuals without apparent subjective complaints. Interestingly, SCD, during advancing preclinical Alzheimer's disease (AD), may denote very early, subtle cognitive decline that cannot be identified using established standardized tests of cognitive performance. The substantial heterogeneity of existing SCD-related research data has led the Subjective Cognitive Decline Initiative (SCD-I) to accomplish an international consensus on the definition of a conceptual research framework on SCD in preclinical AD. In the area of biological markers, the cerebrospinal fluid signature of AD has been reported to be more prevalent in subjects with SCD compared to healthy controls; moreover, there is a pronounced atrophy, as demonstrated by magnetic resonance imaging, and an increased hypometabolism, as revealed by positron emission tomography, in characteristic brain regions affected by AD. In addition, SCD individuals carrying an apolipoprotein epsilon 4 allele are more likely to display AD-phenotypic alterations. The urgent requirement to detect and diagnose AD as early as possible has led to the critical examination of the diagnostic power of biological markers, neurophysiology, and neuroimaging methods for AD-related risk and clinical progression in individuals defined with SCD. Observational studies on the predictive value of SCD for developing AD may potentially be of practical value, and an evidence-based, validated, qualified, and fully operationalized concept may inform clinical diagnostic practice and guide earlier designs in future therapy trials. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Neurovetenskaper0 (SwePub)301052 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Neurosciences0 (SwePub)301052 hsv//eng |
653 | a Alzheimer's disease | |
653 | a biological markers | |
653 | a blood-based biomarkers | |
653 | a cerebrospinal fluid biomarkers | |
653 | a beta-amyloid 1-42 | |
653 | a alzheimers association workgroups | |
653 | a transcranial | |
653 | a magnetic stimulation | |
653 | a cerebrospinal-fluid biomarkers | |
653 | a white-matter | |
653 | a hyperintensities | |
653 | a heterogeneous brain-tissue | |
653 | a gaussian water diffusion | |
653 | a blood-based biomarkers | |
653 | a temporal-lobe atrophy | |
653 | a pittsburgh-compound-b | |
653 | a Neurosciences & Neurology | |
653 | a C 02-04 | |
653 | a 2007 | |
653 | a Las Vegas | |
653 | a NV | |
653 | a V4 | |
653 | a PS98 | |
700 | 1 | a Molinuevo, J. L.4 aut |
700 | 1 | a Cavedo, E.4 aut |
700 | 1 | a Rami, L.4 aut |
700 | 1 | a Amouyel, P.4 aut |
700 | 1 | a Teipel, S. J.4 aut |
700 | 1 | a Garaci, F.4 aut |
700 | 1 | a Toschi, N.4 aut |
700 | 1 | a Habert, M. O.4 aut |
700 | 1 | a Blennow, Kaj,d 1958u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xbleka |
700 | 1 | a Zetterberg, Henrik,d 1973u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xzethe |
700 | 1 | a O'Bryant, S. E.4 aut |
700 | 1 | a Johnson, L.4 aut |
700 | 1 | a Galluzzi, S.4 aut |
700 | 1 | a Bokde, A. L. W.4 aut |
700 | 1 | a Broich, K.4 aut |
700 | 1 | a Herholz, K.4 aut |
700 | 1 | a Bakardjian, H.4 aut |
700 | 1 | a Dubois, B.4 aut |
700 | 1 | a Jessen, F.4 aut |
700 | 1 | a Carrillo, M. C.4 aut |
700 | 1 | a Aisen, P. S.4 aut |
700 | 1 | a Hampel, H.4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi4 org |
773 | 0 | t Journal of Alzheimers Diseased : IOS Pressg 48q 48x 1387-2877x 1875-8908 |
856 | 4 8 | u https://gup.ub.gu.se/publication/224867 |
856 | 4 8 | u https://doi.org/10.3233/jad-150202 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy